About This Report In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA. What's Included in This ...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Louis
+1 718 618 4302
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, ...
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...
Product Synopsis Disease-related, demographic, and desire-led drivers are making health of growing importance to food marketers. However, barriers such as cost, habits, and confusion over how to eat healthily ...
... New congenital heart disease review what matters a commitment to research ensures that services are continually focussed on improvement and development, so networks will be required to have ...
... Conditions back pain musculoskeletal injuries stress minor illnesses the most common causes of short-term absence in non-manual workers (%) source bupa jan 2013 absence statistics 0 20 40 60 80 100 ...
Reportlinker.com © Copyright 2014. All rights reserved.